Bristol-Myers sales and marketing update

The U.K.’s NICE issued two draft guidances requesting Bristol-Myers Squibb make a case for the inclusion of Opdivo nivolumab in the Cancer Drugs Fund (CDF) to treat squamous or non-squamous non-small cell lung cancer (NSCLC). NICE again recommended against Opdivo’s use in the indications for routine use. The recommended dose of Opdivo is 3 mg/kg every two weeks.

According to NICE, the incremental cost-effectiveness ratio (ICER) for Opdivo compared with docetaxel, with the patient access scheme applied, was at least L73,500 ($91,199) per quality-adjusted life year (QALY) gained for squamous NSCLC. For non-squamous NSCLC, the most plausible ICER for Opdivo compared with docetaxel was greater than L80,000 ($99,265) per QALY gained. ...